当中医药遇上数字化 以岭药业携手阿里健康共建过敏性鼻炎数字化疾病中心

Core Viewpoint - Alibaba Health and Yiling Pharmaceutical have signed a strategic cooperation agreement to launch a new innovative traditional Chinese medicine product for allergic rhinitis and to collaborate on patient education and chronic disease management [1][2]. Group 1: Product Launch and Clinical Data - Yiling Pharmaceutical's new drug, Qifang Nasal Tablets, for the treatment of persistent allergic rhinitis, will be launched on Alibaba Health's platform in December 2025 and has been included in the national medical insurance directory [1]. - Clinical trials published in the international journal "Ethnopharmacology" show that after four weeks of treatment, the total nasal symptom score improved by 21.8% and eye symptom improvement was 31% compared to the control group [1]. Group 2: Research and Development Investment - Yiling Pharmaceutical has invested over 5 billion yuan in R&D over the past six years, with R&D expenses accounting for nearly 10% of revenue in the first half of 2025 [2]. - The company has conducted over 40 evidence-based medical studies, with results published in prestigious journals such as the "Journal of the American Medical Association" and "Nature" [2]. Group 3: Health Management and Accessibility - Alibaba Health aims to transform allergic rhinitis management from "passive treatment" to "active health management" by utilizing tools such as pollen season alerts and symptom self-assessment [3]. - The company's pharmaceutical supply chain network spans hundreds of cities, ensuring accessibility to quality medical resources, and has integrated over 250,000 contracted healthcare professionals into its service system [2].